Phase 3 Breast Cancer Trial, Recruiting NCT03417622 Sponsor: Mansoura University Condition: Breast Cancer
Back to Breast Cancer

Phase 3 Breast Cancer Trial, Recruiting

NCT03417622
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have a confirmed diagnosis of invasive breast cancer (adenocarcinoma type), proven by biopsy.
  • People whose tumor falls within a certain size range (stages T1 to T4b — confirm with trial site for what this means in your situation).
  • People whose cancer has not spread extensively to the lymph nodes (nodal stage N0 to N2 — confirm with trial site).
  • People who are considered to be in generally good health or have only mild health conditions, as assessed by a standard medical classification system (ASA class I–II).

Who may not be able to join:

  • People who have chosen, or been advised by their doctor, to have a mastectomy (full breast removal).
  • People who have chosen, or been advised by their doctor, to have surgery as the first treatment (rather than another approach first).
  • People whose cancer has spread to other parts of the body (metastatic cancer).
  • People who have tumours in multiple separate areas of the breast (multifocal tumours).
  • People diagnosed with lobular neoplasia (a specific type of breast tissue change — confirm with trial site).
  • People who are currently pregnant or who have been pregnant within the last 6 months before enrolling.
  • People currently being treated for, or living with, a second active cancer.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +2010 9981 5110

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Mansoura University
Registry
ClinicalTrials.gov
Start date
1 August 2019
Est. completion
1 August 2026

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

Local recurrence rate.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov